Health & Research Goals
IGF-1 DES (Des(1-3)-IGF-1)
IGF-1 DES(1-3) (Variante Truncada de IGF-1)
IGF-1 DES, also known as Des(1-3)-IGF-1, is a truncated analogue of insulin-like growth factor-1 in which the first three N-termin…
Primary Description
IGF-1 DES, also known as Des(1-3)-IGF-1, is a truncated analogue of insulin-like growth factor-1 in which the first three N-terminal amino acids (Gly-Pro-Glu) have been removed. This truncation reduces its affinity for IGF-binding proteins (IGFBPs) by approximately 90%, making it extremely potent in local tissue environments where IGFBPs would otherwise neutralize it. IGF-1 DES is approximately 10 times more potent than native IGF-1 at stimulating muscle growth due to this reduced IGFBP inhibition. The short half-life (~20–30 minutes) combined with extreme local potency makes IGF-1 DES uniquely suited for localized injection protocols targeting specific muscle groups for hyperplasia. It is naturally produced in the gut and brain where IGFBP levels are low. NOTE: This peptide page was not found on PepedHub; content is based on established clinical knowledge.
Key Benefits
- Truncated IGF-1 variant: 2–3× more potent than IGF-1 LR3 in local tissue
- Extremely short half-life produces targeted muscle hypertrophy at injection site
- Does not bind IGF-binding proteins → direct receptor activation
Lyophilized powder stable at -20°C for up to 2 years. Reconstituted: highly unstable — use within 4–7 days at 2–8°C. More labile than IGF-1 LR3. Reconstitute with 0.1% acetic acid. Extremely sensitive to agitation and temperature.
Demonstrated Effects
- ~10x more potent than native IGF-1 in local muscle tissue (90% reduction in IGFBP affinity)
- Highly localized effect when injected intramuscularly — minimal systemic spillover
- Promotes pronounced local muscle hyperplasia (new fiber formation) in targeted muscle groups
- Rapid onset of action suitable for pulsatile post-workout protocols
- Naturally occurring form in the brain and gut — considered more physiological than LR3 in local contexts
- Shorter half-life than LR3 provides controllable, localized action window
- Satellite cell activation and muscle protein synthesis in the injected muscle
- Synergistic with IGF-1 LR3 for dual local + systemic IGF-1 coverage
Proposed Mechanisms of Action
1. IGFBP Bypass (90% Reduced Affinity)
The removal of the first 3 amino acids eliminates the primary IGFBP-binding domain. In normal tissue, 99%+ of IGF-1 is sequestered by IGFBPs. IGF-1 DES bypasses this, remaining free and bioactive in the local tissue microenvironment.
2. IGF-1R Activation (Local)
Full-potency IGF-1R agonist activating PI3K/Akt/mTOR and MEK/ERK pathways in the target tissue. Approximately 10x the local receptor stimulation of equimolar native IGF-1.
3. Satellite Cell Activation (Local)
Localized high-concentration IGF-1R stimulation in the injected muscle drives quiescent satellite cells into proliferation, enabling targeted hyperplasia (new fiber nuclei and fibers) in that specific muscle group.
4. Rapid Clearance After Local Action
The 20–30 minute plasma half-life and high local potency mean IGF-1 DES acts rapidly and locally with less systemic exposure than LR3, reducing systemic side effects while maximizing localized effect.
Research Evidence & Clinical Data
Investigated Applications
Site-Specific Muscle Hyperplasia
Anecdotal: HighThe primary and nearly exclusive community use case. IGF-1 DES injected bilaterally into specific lagging muscle groups immediately post-workout produces localized satellite cell activation and hyperplasia that users report as superior to systemic IGF-1 approaches for targeting specific muscles.
Preclinical basis: Des(1-3)-IGF-1 was shown to produce greater muscle hyperplasia than equimolar native IGF-1 in local injection models due to sustained IGF-1R stimulation without IGFBP neutralization.
Gut and Brain Tissue Repair
Anecdotal: EmergingAs the naturally occurring form of IGF-1 in the gut mucosa and brain, IGF-1 DES may have applications in GI healing and neuroprotection that mirror its physiological role in those tissues where IGFBP levels are naturally low.
Preclinical basis: IGF-1 DES is the dominant IGF-1 form in neonatal brain and gut. Promotes intestinal mucosal growth and neuronal survival in preclinical models.
Safety Profile
Common Side Effects
- Post-injection hypoglycemia (less common than with LR3 due to local action, but still requires glucose monitoring)
- Local muscle soreness or swelling at injection site
- Increased local fullness in injected muscle (temporary)
Contraindications
- Active cancer or cancer history (IGF-1R proliferative signaling)
- Insulin-dependent diabetes (hypoglycemia compounding)
- Pregnancy or breastfeeding
- Active diabetic retinopathy
- Pediatric use
Legal & Regulatory Status
Not approved for human therapeutic use in any jurisdiction. Research chemical only. WADA prohibited at all times (S2 — Peptide Hormones). Not a scheduled controlled substance in most jurisdictions. Generally sold as lyophilized powder for research use only.
No aprobado para uso terapéutico humano en ninguna jurisdicción. Solo químico de investigación. Prohibido por WADA en todo momento (S2 — Hormonas peptídicas). No es una sustancia controlada regulada en la mayoría de jurisdicciones. Generalmente se vende como polvo liofilizado solo para uso de investigación.
Research Protocols
Dosing Protocols
Routes of Administration
intramuscular
Reconstitution Guide
Pharmacokinetics
| Half-Life | ~20–30 minutes in plasma (much shorter than IGF-1 LR3's 20–30 hours). Short half-life limits systemic exposure. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- IGF-1 levels during cycle
- Blood glucose monitoring (especially first few uses)
- Local muscle assessment for disproportionate growth or structural imbalance
- Annual cancer surveillance for repeated users
Critical Warning Signs
- Hypoglycemia (shakiness, confusion) — consume glucose immediately
- Unusual lumps at injection sites
- Any new cancer symptoms
- Severe disproportionate growth at injection sites
Featured in Stacking Protocols
Community-researched combinations involving this compound